We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Combines AI and Machine Learning to Detect Cancer Before It Becomes Visible or Symptomatic

By LabMedica International staff writers
Posted on 28 Dec 2021

A simple blood test combines Artificial Intelligence (AI) and Machine Learning (ML) advances to identify cancer before it is visible or symptomatic. More...

Flagship Pioneering (Cambridge, MA, USA) has launched Harbinger Health (Pune, MH, India), a bioplatform company pioneering the detection of early cancer with a simple blood test that combines AI and ML advances with its recent discoveries about the biology of early cancer. By using this Bio-AI approach to identify cancer before it is visible or symptomatic, Harbinger Health’s proprietary HarbingerHx platform has the potential to create an entirely new paradigm for cancer diagnosis, enabling early therapeutic interventions or prevention.

“Harbinger Health has the potential to revolutionize the way we detect, diagnose, and treat cancer, enabling interventions at a much earlier phase of the disease than is currently possible,” said Doug Cole, M.D., Co-Founder and Chairman, Harbinger Health and Managing Partner, Flagship Pioneering. “Unlike prior approaches that are purely statistical in nature, Harbinger’s approach is informed by its insights into specific biological events that take place early in the development of cancer. After three years of research and development within Flagship Labs, we have created a platform that harnesses these insights to enable high-resolution, blood-based assays. With Harbinger Health, we have the potential to intervene in the cancer continuum far earlier than ever before, thus increasing the opportunities to save more lives.”

“Harbinger Health is poised to redefine our approach to oncology, moving beyond cancer ‘staging,’ and toward early detection that enables the diagnosis and treatment of cancer and ultimately to effectively reduce morbidity and mortality associated with the disease,” said Stephen Hahn, M.D., CEO, Harbinger Health and CEO-Partner, Flagship Pioneering. “We are committed to developing our platform so there is access to early cancer detection for all individuals with a simple test. No one should be disadvantaged in the fight against cancer – it’s our goal to bring the power of this platform not only to those with access to the top cancer centers – but to everyone.”

Related Links:
Flagship Pioneering
Harbinger Health 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Electrolyte Analyzer
BKE-B
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image Credit: 123RF

Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer

Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.